PROKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

PROKIDNEY CORP.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026

$1.40+0.06 (+4.89%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

Dividends

Prokidney has not reported a dividend

No dividend per share appears in Prokidney's annual filings since fiscal 2019.

Where these numbers come from

Parsed from the XBRL in Prokidney's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is PROK.

Revenue growth55.2% · median -24.0%

Operating margin-21664.5% · median -2454.5%

Net margin-10288.4% · median -2344.6%

Company	Revenue	Growth
HUMA	$2.12M	+159.3%
LGVN	$1.19M	-42.7%
PLUR	$1.02M	-24.0%
PROK	$818.00K	+55.2%
SABS	–	–
ARTV	–	–

Company

Next earnings (est.): Nov 9, 2026, during market hours
Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 231
Held by institutions: 15.8%
Auditor: Ernst & Young LLP
SEC CIK: 1850270

Advertisement
300 × 250